Pure class III agents for prevention of sudden cardiac death

Craig M. Pratt

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


The results of clinical trials in postmyocardial infarction patients using type I antiarrhythmic drugs have been disappointing. There was optimism that IKr blockers might result in a reduction in sudden cardiac death in postinfarct population. Four trials are reviewed here, and the results are variable. The four drugs reviewed - d,l-sotalol, d-sotalol, dofetilide, and azimilide - all share IKr-blocking properties. In addition, d,l-sotalol is a beta-blocker and azimilide is an IKs blocker. The primary uses of d,l-sotalol, dofetilide, and, if approved, azimilide are currently for treatment of atrial fibrillation. Thus, the mortality trials reviewed here are primarily used as support of safety in high-risk patients, because none has achieved a mortality reduction in postinfarction patients. These trials play pivotal roles for regulatory approval of these drugs for use in atrial fibrillation.

Original languageEnglish (US)
Pages (from-to)S82-S86
JournalJournal of Cardiovascular Electrophysiology
Issue number9 SUPPL.
StatePublished - Sep 1 2003


  • Antiarrhythmic
  • Azimilide
  • d,l-sotalol
  • d-sotalol
  • Dofetilide
  • Sudden death

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology


Dive into the research topics of 'Pure class III agents for prevention of sudden cardiac death'. Together they form a unique fingerprint.

Cite this